Latest editorial
PHARMACEUTICAL companies Flynn and Pfizer have been fined nearly £70 million after they overcharged the NHS for a life-saving epilepsy drug, the Competition and Markets Authority (CMA) announced today.
The body said that the two drug companies had illegally “abused their dominant positions” in the market to charge unfairly high prices over four years.
Costs to the NHS for the phenytoin sodium drug increased from £2m in 2012 to £50m in 2013.
In the second part of her critique of Wes Streeting’s TenYear Plan for Health, HELEN MERCER looks at the central planks of this privatisation blueprint
Politicians who continue to welcome contracts with US companies without considering the risks and consequences of total dependency in the years to come are undermining the raison d’etre of the NHS, argues Dr JOHN PUNTIS
